Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer

Breast Cancer Research

Table 3 Summary of outcomes reported of trastuzumab beyond disease progression series

Study by country	Patients, number		ORR, percentage		CBR, percentage		TTP, months		OS, months
	First	Second	First	Second	First	Second	First	Second
	HaltT	RetT							HaltT	RetT
Global [18]	77	65	39	32	69	54	5.5	6.1
		105							nr	29
Hellenic [16]		80	nr	24	nr	52	nr	5.2
		80							nr	22.2
German [14]	23	23	56.6	39.1	nr	nr	nr	nr
	113	23							38.5^a	62.4^a
Austrian [21]	54	nr	42.6	25.9	85.2	68.5	6.0	6.0
									nr	nr
Spanish [17]	93	47	46.6	29.8	71	51.1	5.0	4.0
									nr	nr
French [15]			nr	nr	nr	nr	nr	nr
	70	107							4.6^b	NR^b
Italian 1 [20]	184	40	55.4	17.9	nr	nr	9.0	6.3
	71	40							30.2^b	30.1^b
Italian 2 [19]	59	37	59.3	27	83	62.2	9.5	6.7
									nr	nr
Italian 3	57	55	36	17	73	55	7.25	5.25
	23	59							29.9^b	42.3^b

^aOS is calculated from the diagnosis of metastatic disease to the documented date of death. ^bOS is calculated from the day of the first administration of trastuzumab-based therapy to the documented date of death. CBR, clinical benefit rate; HaltT, patients halting trastuzumab; nr, not reported; NR, not reached after median follow-up of 27.8 months; ORR, objective response rate; OS, overall survival; RetT: patients retaining trastuzumab; TTP, time to progression.

ISSN: 1465-542X